Ads
related to: belimumab activating factor supplement- Dosing And Administration
View Information On The Dosing &
Administration Of BENLYSTA.
- Financial Assistance
Out-of-Pocket Costs Keep Climbing.
See How We May Be Able To Help.
- How Does BENLYSTA Work?
Discover Facts Related To The MOA
Of BENLYSTA To Learn How It Works.
- Identifying Patients
Learn How To Identify Patients
Who May Benefit From BENLYSTA.
- Infusion Scheduler Info
Access The Infusion Scheduler For
BENLYSTA To Help Start Patients.
- BENLYSTA Resource Center
Discover A Library Of Resources
Designed To Inform You. Learn More.
- Dosing And Administration
Search results
Results From The WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
B-cell activating factor (BAFF) also known as tumor necrosis factor ligand superfamily member 13B and CD257 among other names, is a protein that in humans is encoded by the TNFSF13B gene. [ 5 ] [ 6 ] BAFF is also known as B Lymphocyte Stimulator (BLyS) and TNF- and APOL-related leukocyte expressed ligand (TALL-1) and the Dendritic cell-derived ...
nerve growth factor (NGF) [36] Y: pain associated with osteoarthritis in dogs [36] Begelomab [6] mab: mouse: DPP4: Belantamab mafodotin [5] Blenrep: mab: humanized: B-cell maturation antigen (BCMA) Y (Withdrawn) relapsed or refractory multiple myeloma Belimumab [37] Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus ...
Berberine supplements, on the other hand, activate AMPK enzymes in your body, which work to regulate metabolism (offering potential benefits for weight loss), Lee says.
Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. [1] It is currently under active investigation in clinical trials. [2]
Treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who are receiving routine prophylaxis and without pre-existing neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid detected by an FDA-approved test. [3] Nemolizumab: Treatment of adults with Prurigo Nodularis [2]
A discredited study that set off a flurry of interest in using an antimalarial drug to treat COVID-19 has now been formally withdrawn. A scientific journal on Tuesday retracted the March 2020 ...
This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.